Novartis, Alcon Join Alnylam in Opposing Silence Patent in Europe
Novartis, Alcon Join Alnylam in Opposing Silence Patent in Europe
Drug makers Novartis and Alcon have joined Alnylam Pharmaceuticals in opposing a European patent held by Silence Therapeutics covering a key RNAi molecule-design technology, according to documents on file with the European Patent Office.